Please use this identifier to cite or link to this item:
Scopus Web of ScienceĀ® Altmetric
Type: Journal article
Title: Assessment of early paraprotein response to vincristine-doxorubicin-dexamethasone chemotherapy may help guide therapy in multiple myeloma
Author: Ross, D.
To, L.
Horvath, N.
Citation: Internal Medicine Journal, 2004; 34(9-10):576-578
Publisher: Blackwell Publishing Asia
Issue Date: 2004
ISSN: 1444-0903
Abstract: Vincristine, doxorubicin and dexamethasone (VAD) are commonly used as the initial chemotherapy in myeloma patients prior to high-dose therapy and autologous stem cell transplantation. We reviewed monoclonal protein responses and survival of 62 patients treated in this way. Among patients with IgG paraprotein, achievement of at least 50% reduction in paraprotein after the first cycle of VAD correlated with significantly better event-free survival at 3 years, compared with those having less than 50% response. We postulate that early paraprotein response may be used to identify high risk patients.
Keywords: Autologous transplantation
Multiple myeloma
Prognostic factors
Rights: Copyright status unknown
DOI: 10.1111/j.1445-5994.2004.00689.x
Published version:
Appears in Collections:Aurora harvest
Pathology publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.